Abstract: The present disclosure relates generally to a pharmaceutical compositions and methods of reducing acetaminophen-induced liver toxicity. The disclosure includes pharmaceutical compositions including acetaminophen and one or more components selected from S-adenosylhomocysteine (SAH), S-methylmethionine (SMM), or a pharmaceutically acceptable salt thereof. The disclosure also relates to methods of reducing acetaminophen-induced liver toxicity in a subject by administering or co-administering one or more of S-adenosylhomocysteine (SAH), S-methylmethionine (SMM), or a pharmaceutically acceptable salt thereof, with acetaminophen to a subject.

Abstract: The present disclosure relates generally to a co-formulation or co-administration of acetaminophen with one or more chemicals that are metabolites or their derivatives in the methionine and glutathione biosynthesis pathways, for protection against acetaminophen-induced liver toxicity. The formulation may comprise acetaminophen and diet supplements such as S-methylmethionine (SMM). The present disclosure also encompasses methods of providing pain or fever relief with protection against acetaminophen-induced liver injury with the formulations described herein. Embodiments of the present disclosure also include co-formulation or co-administration of an agent and one or more other chemicals for reducing agent-induced liver toxicity via depletion of glutathione.

Abstract: The present invention relates to polymorphisms of the FRZB gene and the analysis of nucleic acids thereof. The invention further relates to methods of predicting risks of certain conditions in individual and kits for the determination of such risks.

Abstract: Methods and reagents for determining the genotoxicity of a compound based on genomic responses to contact therewith are provided.

Abstract: A method of associating a phenotype with one or more candidate chromosomal regions in a genome of an organism includes the step of deriving a phenotypic data structure that represents differences in phenotypes between different strains of the organism. Further, a genotypic data structure is established. The genotypic data structure corresponds to a locus selected from a plurality of loci in the genome of the organism. The genotypic data structure represents variations of at least one component of the locus between different strains of the organism. The phenotypic data structure is compared to the genotypic data structure to form a correlation value. The process of establishing a genotypic data structure and comparing it to the phenotypic data structure is repeated for each locus in the plurality of loci, thereby identifying one or more genotypic data structures that form a high correlation value relative to all other compared genotypic data structures.

Abstract: Computer systems, computer program products and methods for processing an input nucleic acid chromatogram having a plurality of substantially simultaneous traces. Each trace in the plurality of traces has a plurality of datapoints. Each respective datapoint in each of the plurality of datapoints represents a signal amplitude at a position in the trace corresponding to the respective datapoint. A first peak is identified in a first trace that is substantially overlapping a second peak in a second trace in the plurality of traces. The first peak is outputted to a first output homozygous representation and the second peak is outputted to a second output homozygous representation. The first output homozygous representation is a first homozygous sequence representation or a first homozygous nucleic acid chromatogram corresponding to the input nucleic acid chromatogram.

Abstract: A database of genetic variations is analyzed to produce a haplotype map of the genome for strains of a single species. A computational method is used to rapidly map complex phenotypes onto the haplotype blocks within the haplotype map. The specific genetic locus regulating three different biologically important phenotypic traits in mice is identified using these systems and methods.

Abstract: Methods and reagents for determining sequence variants present at the TCF-1 locus, which facilitates identifying individuals at risk for Th1 diseases, such as type 1 diabetes or multiple sclerosis, or Th2 diseases, such as allergic asthma or atopy.

Abstract: Methods and reagents for determining sequence variants present at the TCF-1 locus, which facilitates identifying individuals at risk for Th1 diseases, such as type 1 diabetes or multiple sclerosis, or Th2 diseases, such as allergic asthma or atopy.

Abstract: Methods of treating and preventing bone loss and/or enhancing bone formation are disclosed. The methods utilize 15-lipoxygenase inhibitors. These molecules can be delivered alone or in combination with agents which inhibit bone resorption or additional agents that regulate calcium resorption from bone or enhances bone accumulation. The invention additionally provides methods of diagnosing a predisposition to bone loss.

Abstract: Methods and reagents for determining sequence variants present at the TCF-1 locus, which facilitates identifying individuals at risk for Th1 diseases, such as type 1 diabetes or multiple sclerosis, or Th2 diseases, such as allergic asthma or atopy.

Abstract: This invention relates to inhibitors of glycogen synthase kinase-3&bgr;, methods of treating diseases characterized by an excess of Th2 cytokines, and to 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives of Formula (I): 1

Abstract: This invention relates to inhibitors of glycogen synthase kinase-3&bgr;, methods of treating diseases characterized by an excess of Th2 cytokines, and to 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives of Formula (I): that are inhibitors of glycogen synthase kinase -3&bgr;, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

Abstract: A method of associating a phenotype with one or more candidate chromosomal regions in a genome of an organism includes the step of deriving a phenotypic data structure that represents differences in phenotypes between different strains of the organism. Further, a genotypic data structure is established. The genotypic data structure corresponds to a locus selected from a plurality of loci in the genome of the organism. The genotypic data structure represents variations of at least one component of the locus between different strains of the organism. The phenotypic data structure is compared to the genotypic data structure to form a correlation value. The process of establishing a genotypic data structure and comparing it to the phenotypic data structure is repeated for each locus in the plurality of loci, thereby identifying one or more genotypic data structures that form a high correlation value relative to all other compared genotypic data structures.

Abstract: A method of associating a phenotype with one or more candidate chromosomal regions in a genome of an organism includes the step of deriving a phenotypic data structure that represents differences in phenotypes between different strains of the organism. Further, a genotypic data structure is established. The genotypic data structure corresponds to a locus selected from a plurality of loci in the genome of the organism. The genotypic data structure represents variations of at least one component of the locus between different strains of the organism. The phenotypic data structure is compared to the genotypic data structure to form a correlation value. The process of establishing a genotypic data structure and comparing it to the phenotypic data structure is repeated for each locus in the plurality of loci, thereby identifying one or more genotypic data structures that form a high correlation value relative to all other compared genotypic data structures.

Abstract: This invention relates to inhibitors of glycogen synthase kinase-3&bgr;, methods of treating diseases characterized by an excess of Th2 cytokines, and to 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives of Formula (I): 1

Abstract: Truncated forms of inhibitory kappa B protein (I&kgr;B-&agr;), nucleic acids encoding the truncates, expression and delivery vectors, and therapeutic and prophylatic uses thereof are provided.